Forest plot of efficacy of MTX in psoriasis as reported in the published clinical studies shown in Table 4.

<p>The risk ratio shown refers to the PASI75 outcome reported at 12 or 16 weeks, respectively, assuming a random effects model (<a href="http://ije.oxfordjournals.org/content/39/2/421.full" target="_blank">http://ije.oxfordjournals.org/content/39/2/421.full</a>). One study (Dogra 2012) is listed twice because two distinct sub-cohorts were dosed differently (10 mg vs 25 mg), as described in the text.</p

Adverse effects associated with MTX treatments in published trials¹.

<p>Adverse effects associated with MTX treatments in published trials<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153740#t002fn001" target="_blank">¹</a>.</p

Assessment of bias-profile in published trials on MTX efficacy in psoriasis¹.

<p>Assessment of bias-profile in published trials on MTX efficacy in psoriasis<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153740#t004fn001" target="_blank">¹</a>.</p

Treatment limiting AEs occurring under methotrexate treatment¹.

<p>Treatment limiting AEs occurring under methotrexate treatment<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0153740#t003fn001" target="_blank">¹</a>.</p

PRISMA flow diagram according to [50] summarising study selection for clinical trials reporting safety (left) and efficacy (right) outcomes, respectively.

<p>Search terms employed were: methotrexate [Title] AND (psoriasis [Title] OR arthritis [Title] OR Crohn’s [Title] OR ulcerative colitis [Title] OR ankylosing spondylitis [Title]) AND (trial [Title] OR Study [Title]) for safety studies and: Search: methotrexate [Title] AND psoriasis [Title] AND (trial [Title] OR Study [Title]) for efficacy studies.</p

Forest plot of all non treatment limiting adverse effects (Fig3a), as reported in the studies summarised in Table 2, as well as limiting AEs (Fig 3b).

<p>All individual study data and forest plots for all individual AE’s are detailed in the Supplement. Underlined studies were conducted for psoriasis as indication.</p

The change in the number of patients receiving topical psoriasis- treatments after one course of NB-UVB phototherapy¹.

<p>The change in the number of patients receiving topical psoriasis- treatments after one course of NB-UVB phototherapy<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181813#t002fn001" target="_blank">¹</a>.</p

The effect of NB-UVB on drug prescribing.

<p>A. Top: Prescription of psoriasis-related (left) and–unrelated (right) drugs in psoriasis patients before (dark) and after (light shaded) NB-UVB phototherapy. H1 –antihistamine, Depr–anti-depressive drugs, HTN–antihypertensive drugs (for details see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181813#sec006" target="_blank">Methods</a>). Shown is the percentage of patients on treatment. *** p <0.0001 (Qui-square); bottom: the number of scripts per patient in patients receiving treatment (data shown represent average ± s.e.m.). * p < 0.01 in a two-sided T-test. B. Histogram plots showing the overall distribution of prescriptions filled for the topical treatment classes psoriasis before (solid) and after NB-UVB (dashed), respectively.</p

The change in prescriptions per patient after NB-UVB phototherapy¹.

<p>The change in prescriptions per patient after NB-UVB phototherapy<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181813#t003fn001" target="_blank">¹</a>.</p

Clinical outcomes of NB-UVB treatment for psoriasis, and change in topical prescriptions made out for psoriasis, at four independent treatment sites, as indicated (b).

<p>A, pie chart showing the percentage of the overall treatment cohort (n = 1749) receiving treatment at each individual site. B, The percentage of patients at each site exhibiting either a reduction, or increase in the number of topical prescriptions made out for psoriasis after compared to before NB-UVB treatment. C, The clinical outcome recorded at each site, shown as percent of patients assessed for each outcome. (Outcome classes are identical to those shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181813#pone.0181813.g002" target="_blank">Fig 2</a>, above). D, The number of treatment session administered per NB-UVB course (average ± s.d.)</p